Biocon Biologics Set to Launch Denosumab Biosimilars in the U.S. Market Biocon Biologics has secured entry into the U.S. market for their denosumab biosimilars, Bosaya™ and Aukelso™, enhancing treatment options for osteoporosis and cancer-related bone conditions.

Biocon Biologics Set to Launch Denosumab Biosimilars in the U.S. Market #United_States #Bridgewater #Biocon_Biologics #Bosaya #Aukelso

Biocon Biologics Celebrates FDA Approval of Two Critical Biosimilars, Bosaya™ and Aukelso™ Biocon Biologics has received FDA approval for its new biosimilars, Bosaya™ and Aukelso™, aimed at enhancing access to vital therapies for osteoporosis and oncology.

Biocon Biologics Celebrates FDA Approval of Two Critical Biosimilars, Bosaya™ and Aukelso™ #India #Bengaluru #Biocon_Biologics #Bosaya #Aukelso